# EDGAR Filing Document

**Accession Number:** 0000873303
**File Stem:** 0001193125-26-257643
**Filing Date:** 2026-6
**Character Count:** 25835
**Document Hash:** 75a9fca08cc52a12c0b11061919ef4ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-257643.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001193125-26-257643

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260604

**DATE AS OF CHANGE**: 20260604

**EFFECTIVENESS DATE**: 20260604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sarepta Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000873303
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 930797222
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296501
- **FILM NUMBER:** 261065764

**BUSINESS ADDRESS:**
- **STREET 1:** 215 FIRST STREET
- **STREET 2:** SUITE 415
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-274-4000

**MAIL ADDRESS:**
- **STREET 1:** 215 FIRST STREET
- **STREET 2:** SUITE 415
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sarepta Therapuetics, Inc.
- **DATE OF NAME CHANGE:** 20120712

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVI BIOPHARMA INC
- **DATE OF NAME CHANGE:** 19980930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANTIVIRALS INC
- **DATE OF NAME CHANGE:** 19970123

**As filed with the Securities and Exchange Commission on June 4, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## SAREPTA THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

**Delaware** 

**(State or other jurisdiction of incorporation or organization)** 

**93-0797222** 

**(IRS Employer Identification No.)** 

**215 First Street, Suite 415** 

**Cambridge, Massachusetts 02142** 

**(Address of Principal Executive Offices) (Zip Code)** 

**Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan** 

**Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

**Douglas S. Ingram** 

**Chief Executive Officer** 

**Sarepta Therapeutics, Inc.** 

**215 First Street, Suite 415** 

**Cambridge, Massachusetts 02142** 

**(Name and address of agent for service)** 

**(617) 274-4000** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Paul M. Kinsella** 

**William J. Michener** 

**Ropes & Gray LLP** 

**Prudential Tower** 

**800 Boylston Street** 

**Boston, MA 02119** 

**(617) 951-7000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**INTRODUCTION** 

This Registration Statement is being filed to register: (a) 6,286,841 shares of the Registrant's common stock, par value $0.0001 per share ("Common Stock"), available for issuance under the Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan (the "2026 Plan") and (b) 1,500,000 shares of Common Stock available for issuance under the Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan (the "2026 ESPP"). The 2026 Plan and 2026 ESPP were adopted by the Registrant's Board of Directors on April 22, 2026 and were approved by the Registrant's stockholders on June 4, 2026.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission").

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3.** **Incorporation of Documents by Reference.** <br>

The information incorporated by reference herein is considered to be part of this Registration Statement, and later information filed with the Commission will update and supersede this information. The following documents filed by the Registrant with the Commission are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm) for the fiscal year ended December 31, 2025 filed on March 2, 2026, including information specifically incorporated by reference into the Form 10-K from the Registrant's [Definitive Proxy Statement](http://www.sec.gov/Archives/edgar/data/873303/000119312526177247/srpt-20260424.htm) for its 2026 Annual Meeting of Stockholders, filed by the Registrant with the Commission on
April 24, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Registrant's Quarterly Report on [Form 10-Q](http://www.sec.gov/Archives/edgar/data/873303/000119312526208893/srpt-20260331.htm) for the quarterly period ended March 31, 2026 filed by the Registrant with the Commission on May 6, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Registrant's Current Reports on Form 8-K, filed by the
Registrant with the Commission on [February 25, 2026](http://www.sec.gov/Archives/edgar/data/873303/000119312526072064/srpt-20260225.htm) and [June 4, 2026](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/873303/000119312526257501/d88936d8k.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The description of the Registrant's Common Stock contained in the Registrant's Annual Report on
Form [8-K12B](http://www.sec.gov/Archives/edgar/data/873303/000119312513250177/d548510d8k12b.htm) , filed by the Registrant with the Commission on June 6, 2013, as the description therein has
been updated and superseded by the description of our capital stock contained in Exhibit 4.4 to our Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/873303/000156459020006769/srpt-10k_20191231.htm) for the fiscal year ended December 31, 2019, as filed with the Commission on February 26, 2020, and including any amendments or reports filed for the purpose of updating such description.

All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act of 1934, as amended (the "Exchange Act"), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document, or current report furnished under Items 2.02 or 7.01 of Form 8-K, that is not deemed filed with the Commission. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

**Item 4.** **Description of Securities.** <br>

Not applicable.

**Item 5.** **Interests of Named Experts and Counsel.** <br>

Not applicable.

**Item 6.** **Indemnification of Directors and Officers.** <br>

The Registrant is a Delaware corporation. As permitted by subsection (b)(7) of Section 102 of the Delaware General Corporation Law (the "DGCL"), our amended and restated certificate of incorporation contains a provision eliminating the personal liability of our directors for monetary damages for violations of the director's fiduciary duty, provided that such provision may not eliminate or limit the liability of a director (i) for any breach of the director's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DCGL, or (iv) for any transaction from which the director derived an improper personal benefit. No such provision may eliminate or limit the liability of a director for any act or omission occurring prior to the date when such provision became effective.

Section 145 of the DGCL authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act. Our amended and restated certificate of incorporation permits indemnification of our directors and officers to the maximum extent permitted by the DGCL, and our amended and restated bylaws provide for indemnification of our directors and officers and permits indemnification of employees and other agents to the maximum extent permitted by the DGCL.

We have entered into indemnification agreements with certain of our directors and officers containing provisions that provide indemnification rights to the fullest extent permitted by the DGCL, subject to certain exceptions. The indemnification agreements require us, among other things, to indemnify our directors and officers against certain liabilities that may arise by reason of their status or service as directors and officers and to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified.

We carry director and officer liability insurance.

**Item 7.** **Exemption From Registration Claimed.** <br>

Not applicable.

**Item 8.** **Exhibits.** <br>

**EXHIBIT INDEX** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference to Filings Indicated** | **Incorporated by Reference to Filings Indicated** | **Incorporated by Reference to Filings Indicated** | **Incorporated by Reference to Filings Indicated** | **Incorporated by Reference to Filings Indicated** |
| <br>**Exhibit <br>Number** | <br>**Description** | **Form** | **File No.** | **Exhibit** | **Filing<br>Date** | **Provided<br>Herewith** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/873303/000119312526257501/d88936dex101.htm) | 8-K | 001-14895 | 10.1 | 6/4/26 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/873303/000119312526257501/d88936dex102.htm) | 8-K | 001-14895 | 10.2 | 6/4/26 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Ropes & Gray LLP](d158109dex51.htm) |  |  |  |  | X |
| 23.1 | [Consent of KPMG LLP, independent registered public accounting firm.](d158109dex231.htm) |  |  |  |  | X |

---

------

---

| | | |
|:---|:---|:---|
| 23.2 | [Consent of Ropes & Gray LLP (included in Exhibit 5.1).](d158109dex51.htm) | X |
| 24.1 | [Powers of Attorney (included in the signature page to this Registration Statement).](#tx158109_1) | X |
| 107 | [Filing Fee Table](d158109dexfilingfees.htm) | X |

---

**Item 9.** **Undertakings.** <br>

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made pursuant to this Registration Statement, a
post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

*Provided*, *however*, that: paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to
Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial *bona fide* offering thereof.

------

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the provisions described under "Item 6—Indemnification of Directors and Officers," or otherwise, the Registrant has been advised that in the opinion of the Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 4th day of June, 2026.

---

| | |
|:---|:---|
| SAREPTA THERAPEUTICS, INC. | SAREPTA THERAPEUTICS, INC. |
| By: | /s/ Douglas S. Ingram |
| Name:<br> Title: | Douglas S. Ingram<br> Chief Executive Officer and Director |

---

**POWER OF ATTORNEY** 

Each person whose signature appears below hereby constitutes and appoints Ryan H. Wong, Ian M. Estepan and Cristin L. Rothfuss, and each of them singly, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Sarepta Therapeutics, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities indicated below on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Douglas S. Ingram<br> Douglas S. Ingram | Chief Executive Officer and Director<br> (Principal Executive Officer) | June 4, 2026 |
| /s/ Ryan H. Wong<br> Ryan H. Wong | Executive Vice President, Chief Financial Officer<br> (Principal Financial and Accounting Officer) | June 4, 2026 |
| /s/ M. Kathleen Behrens, Ph.D.<br> M. Kathleen Behrens, Ph.D. | Chairwoman of the Board | June 4, 2026 |
| /s/ Richard J. Barry<br> Richard J. Barry | Director | June 4, 2026 |
| /s/ Kathryn J. Boor, Ph.D.<br> Kathryn J. Boor, Ph.D. | Director | June 4, 2026 |
| /s/ Michael A. Chambers<br> Michael A. Chambers | Director | June 4, 2026 |
| /s/ Deirdre Connelly<br> Deirdre Connelly | Director | June 4, 2026 |
| /s/ Stephen L. Mayo, Ph.D.<br> Stephen L. Mayo, Ph.D. | Director | June 4, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Claude Nicaise, M.D.<br> Claude Nicaise, M.D. | Director | June 4, 2026 |
| /s/ Hans Wigzell, M.D., Ph.D.<br> Hans Wigzell, M.D., Ph.D. | Director | June 4, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g158109g0604131601909.jpg) | ROPES & GRAY LLP<br> PRUDENTIAL TOWER<br> 800 BOYLSTON STREET<br> BOSTON, MA 02199-3600<br> WWW.ROPESGRAY.COM |

---

June 4, 2026

Sarepta Therapeutics, Inc.

215 First Street, Suite 415

Cambridge, Massachusetts 02142

Ladies and Gentlemen:

This opinion letter is furnished to you in connection with the registration statement on Form S-8 (the "<u>Registration Statement</u>"), filed by Sarepta Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of 7,786,841 shares of Common Stock, $0.0001 par value, of the Company (the "<u>Shares</u>"). The Shares are issuable under the Company's 2026 Equity Incentive Plan (the "<u>2026 Plan</u>") and the Company's 2026 Employee Stock Purchase Plan (the "<u>ESPP</u>" and together with the 2026 Plan, the "<u>Plans</u>").

We are familiar with the actions taken by the Company in connection with the adoption of the Plans. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the Plans, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

------

Sarepta Therapeutics, Inc. - 2 -

---

| |
|:---|
| Very truly yours, |
| /s/ Ropes & Gray LLP |
| Ropes & Gray LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the use of our report dated March 2, 2026, with respect to the consolidated financial statements of Sarepta Therapeutics, Inc., and the effectiveness of internal control over financial reporting, incorporated herein by reference.

/s/ KPMG LLP

Boston, Massachusetts

June 4, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Sarepta Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan-Common Stock, par value $0.0001 per share | Other | 6286841 | $16.31 | $102538377.71 | 0.0001381 | $14160.55 |
| 2 | Equity | Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan-Common Stock, par value $0.0001 per share | Other | 1500000 | $16.31 | $24465000.00 | 0.0001381 | $3378.62 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $127003377.71  |  | $17539.17  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $17539.17  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (2) Represents 6,286,841 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on June 3, 2026.

<sup>2</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on June 3, 2026. (4) Represents 1,500,000 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---